MedPath

Study to Evaluate the Safety and Efficacy of Androxal™ Treatment in Men With Secondary Hypogonadism

Phase 3
Completed
Conditions
Secondary Hypogonadism
Interventions
Registration Number
NCT00962637
Lead Sponsor
Repros Therapeutics Inc.
Brief Summary

Approximately 4 to 5 million men in the U.S. are testosterone-deficient. Enclomiphene (trans-clomiphene) citrate (Androxal) was evaluated to determine if Androxal increased serum testosterone levels in men with secondary hypogonadism. Subjects were randomly assigned to 1 of 4 treatments groups. Appropriate amounts of medications were dispensed at each visit. Subjects took their medications orally or by rubbing it onto the skin (depending on the treatment assignment) once daily for up to 6 months. Treatment visits occurred at approximately 4-week intervals for Months 1, 2, and 3 and then at 6-week intervals for Months 4, 5, and 6.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
194
Inclusion Criteria
  • Total serum testosterone concentrations < 300 ng/dL at baseline
Exclusion Criteria
  • Presence or history of prostate cancer
  • Elevated PSA > 3.5 ng/mL

Additional inclusion and exclusion criteria may apply.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
4PlaceboPlacebo
1AndroxalAndroxal™ 12.5 mg
2AndroxalAndroxal™ 25 mg
3AndroGelAndroGel®
Primary Outcome Measures
NameTimeMethod
Evaluate the safety of Androxal™ administered in men with secondary hypogonadismSix months
Secondary Outcome Measures
NameTimeMethod
Demonstrate that treatment of men with secondary hypogonadism with Androxal™ was non-inferior to treatment with the active control, AndroGel®Six months

Trial Locations

Locations (18)

Alabama Clinical Therapeutics, LLC

🇺🇸

Birmingham,, Alabama, United States

Medical Affiliated Research Center, Inc.

🇺🇸

Huntsville, Alabama, United States

Northern California Research Corp.

🇺🇸

Carmichael, California, United States

Prime-Care Clinical Research

🇺🇸

Mission Viejo, California, United States

Harbor-UCLA Medical Center

🇺🇸

Torrance, California, United States

Chase Medical Research, LLC

🇺🇸

Waterbury, Connecticut, United States

Southeastern Research Group, Inc.

🇺🇸

Tallahassee, Florida, United States

Northeast Indiana Research, LLC

🇺🇸

Fort Wayne, Indiana, United States

Commonwealth Biomedical Research

🇺🇸

Madisonville, Kentucky, United States

The Center for Sexual Medicine at Sheppard Pratt

🇺🇸

Baltimore, Maryland, United States

Scroll for more (8 remaining)
Alabama Clinical Therapeutics, LLC
🇺🇸Birmingham,, Alabama, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.